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Summary
Background People with severe mental illnesses, including psychosis, have an increased risk of cardiovascular disease. 
We aimed to evaluate the effects of a primary care intervention on decreasing total cholesterol concentrations and 
cardiovascular disease risk in people with severe mental illnesses.
Methods We did this cluster randomised trial in general practices across England, with general practices as the cluster 
unit. We randomly assigned general practices (1:1) with 40 or more patients with severe mental illnesses using a 
computer-generated random sequence with a block size of four. Researchers were masked to allocation, but patients 
and general practice staff were not. We included participants aged 30–75 years with severe mental illnesses 
(schizophrenia, bipolar disorder, or psychosis), who had raised cholesterol concentrations (5·0 mmol/L) or a 
total:HDL cholesterol ratio of 4·0 mmol/L or more and one or more modifiable cardiovascular disease risk factors. 
Eligible participants were recruited within each practice before randomisation. The Primrose intervention consisted 
of appointments (≤12) with a trained primary care professional involving manualised interventions for cardiovascular 
disease prevention (ie, adhering to statins, improving diet or physical activity levels, reducing alcohol, or quitting 
smoking). Treatment as usual involved feedback of screening results only. The primary outcome was total cholesterol 
at 12 months and the primary economic analysis outcome was health-care costs. We used intention-to-treat analysis. 
The trial is registered with Current Controlled Trials, number ISRCTN13762819.
Findings Between Dec 10, 2013, and Sept 30, 2015, we recruited general practices and between May 9, 2014, and 
Feb 10, 2016, we recruited participants and randomly assigned 76 general practices with 327 participants to the 
Primrose intervention (n=38 with 155 patients) or treatment as usual (n=38 with 172 patients). Total cholesterol 
concentration data were available at 12 months for 137 (88%) participants in the Primrose intervention group and 
152 (88%) participants in the treatment-as-usual group. The mean total cholesterol concentration did not differ at 
12 months between the two groups (5·4 mmol/L [SD 1·1] for Primrose vs 5·5 mmol/L [1·1] for treatment as usual; 
mean difference estimate 0·03, 95% CI –0·22 to 0·29; p=0·788). This result was unchanged by pre-agreed supportive 
analyses. Mean cholesterol decreased over 12 months (–0·22 mmol/L [1·1] for Primrose vs –0·36 mmol/L [1·1] for 
treatment as usual). Total health-care costs (£1286 [SE 178] in the Primrose intervention group vs £2182 [328] in the 
treatment-as-usual group; mean difference –£895, 95% CI –1631 to –160; p=0·012) and psychiatric inpatient costs 
(£157 [135] vs £956 [313]; –£799, –1480 to –117; p=0·018) were lower in the Primrose intervention group than the 
treatment-as-usual group. Six serious adverse events of hospital admission and one death occurred in the Primrose 
group (n=7) and 23, including three deaths, occurred in the treatment-as-usual group (n=18).
Interpretation Total cholesterol concentration at 12 months did not differ between the Primrose and treatment-as-
usual groups, possibly because of the cluster design, good care in the treatment-as-usual group, short duration of the 
intervention, or suboptimal focus on statin prescribing. The association between the Primrose intervention and fewer 
psychiatric admissions, with potential cost-effectiveness, might be important.
Funding National Institute of Health Research Programme Grants for Applied Research.
Copyright © The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license.
Introduction
An increased risk of cardiovascular disease morbidity 
and mortality in people with severe mental illnesses is 
well established, including schizophrenia, psychoses, 
and bipolar affective disorder.1 This health inequality has 
been recognised for many years but the latest evidence 
suggests that the mortality gap continues to widen, partly 
because gains from primary prevention in the general 
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population have not been observed to the same degree in 
people with severe mental illnesses.2,3 Less evidence 
exists regarding which interventions effectively decrease 
the cardiovascular risk in people with severe mental 
illnesses, and few studies have taken a pragmatic 
or multi-risk factor approach to decreasing the 
cardiovascular disease risk in real-life settings. 
Interventions focused on single risk factors have shown 
some promise, including smoking cessation4 and weight 
reduction,4,5 and statins have been shown to decrease 
cholesterol concentrations effectively in large studies6 of 
people with severe mental illnesses. Based on economic 
modelling, screening for cardiovascular disease risk in 
people with severe mental illnesses (with risk algorithms) 
and prescribing statins for those individuals with a 
10-year risk of more than 10%, might be cost-effective in 
UK primary care.7
We developed a pragmatic intervention aimed at 
reducing cardiovascular disease risk factors among 
people with severe mental illnesses in primary care in 
England, using published evidence and evidence from 
focus groups,8 and incorporating scientific behaviour 
change theory.9 Nurses and health-care assistants were 
trained to deliver the intervention and to target relevant 
cardiovascular disease risk factors in a collaborative way, 
with recommended risk reduction strategies for the 
participant risk profile. We selected the cluster trial 
design to minimise the risk of contamination of the 
intervention between the trial groups. Our aims were to 
compare the clinical effectiveness and cost-effectiveness 
of the intervention versus treatment as usual for people 
with severe mental illnesses.
Methods
Study design and participants
We did this cluster randomised trial with general practices 
from across England as the unit of cluster. We included 
people aged 30–75 years on the Quality and Outcomes 
Framework register for severe mental illnesses, including 
schizophrenia, bipolar affective disorder, or other non-
organic psychosis, with a mean total cholesterol 
concentration of 5·0 mmol/L or a total:HDL cholesterol 
ratio of 4·0 mmol/L or more and one or more additional 
cardiovascular disease risk factors, including hypertension, 
diabetes, raised glycated haemoglobin (HbA1c; 
42–47 mmol/mol), raised body-mass index (BMI; 
>30 kg/m²), or current smoker.10 We excluded people 
currently under the care of acute psychiatric services, with 
organic psychoses or personality disorder diagnoses, with 
less than 6 months life expectancy, pre-existing 
cardiovascular disease, or who were pregnant. General 
practices in England were eligible to participate in the 
study if they had an available nurse or health-care assistant 
who could deliver the intervention and at least 40 patients 
on their practice register with severe mental illness. Data 
from screening, baseline assessments, and follow-up 
were collected in the general practices from patient 
questionnaires and medical records by research nurses.
The trial was delivered according to the published 
protocol.10 Ethics approval was obtained from the 
Research in context
Evidence before this study
People with severe mental illnesses have an increased risk of 
morbidity and mortality from cardiovascular disease compared 
with the general population. We searched for randomised 
controlled trials of interventions to reduce cardiovascular disease 
risk in people with severe mental illnesses published in English. 
On May 19, 2014, we searched the Cochrane Library for existing 
systematic reviews and the Cochrane Depression, Anxiety and 
Neurosis, and Cochrane Schizophrenia Group Trial Registers for 
additional randomised controlled trials from January, 1966, 
using the search terms: (schizophrenia OR severe mental illness 
OR bipolar OR mania OR manic OR hypomani OR psychos OR 
psychotic OR postpsychotic OR post psychotic OR rapid cycling 
OR schizoaffective) AND (physical OR cardio OR metabolic OR 
weight OR tobacc OR smok OR medical OR alcohol OR nutrition 
OR diet OR health OR diabete OR blood pressure OR hypertension 
OR cholesterol OR statin). 11 026 papers were identified, of 
which 15 systematic reviews and 28 randomised controlled trials 
were relevant. Although some evidence existed for effectiveness 
for pharmacological and behavioural interventions targeting 
weight (metformin, topirimate, diet, and exercise) and smoking 
(bupropion, nicotine replacement therapy, and standardised 
stop smoking services), we found no evidence for interventions 
targeting cholesterol, hypertension, diabetes, or multiple 
cardiovascular disease risk factors. Most trials had small sample 
sizes, short length of follow-up, and were done in secondary care, 
which limited their generalisability to other settings.
Added value of this study
To our knowledge, this is the first pragmatic cluster randomised 
controlled trial of a behavioural change intervention targeting 
multiple cardiovascular disease risk factors in people with 
severe mental illnesses compared with treatment as usual in 
primary care in England. The primary outcome of total 
cholesterol at the 12-month follow-up did not differ between 
the intervention (Primrose) and treatment-as-usual groups; 
however, psychiatric inpatient and total health-care costs were 
lower in the Primrose group and total cholesterol 
concentrations decreased in both groups at 12 months.
Implications of all the available evidence
The decrease in admissions and costs with the Primrose 
intervention might be important. General practices should 
continue to optimise evidence-based treatments for 
cardiovascular disease prevention in people with severe 
mental illnesses with the same interventions used in the 
general population.
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City Road and Hampstead Research Ethics Committee 
(reference number 12/LO/1934; approval granted 
Jan 10, 2013). Local National Health Services approvals 
were obtained before the start of each recruitment wave 
from regional research and development departments.
Randomisation and masking
We randomly assigned general practices to the Primrose 
intervention or treatment as usual (1:1) using a computer-
generated random sequence with an undisclosed fixed 
block size of four to facilitate blinding. The randomisation 
was done by a senior statistician from the local Clinical 
Trials Unit (PRIMENT) who was not involved in the 
Primrose trial. The allocation was communicated to the 
practices by the Primrose trial manager.
It was not possible to mask patients or general practice 
staff, including nurses and health-care assistants, to the 
treatment allocation. However, the researchers collecting 
the outcome data were masked to allocation, as were the 
statisticians and health economists doing the analysis 
(the randomisation variable was kept separate from the 
main dataset without a label).
Eligible participants were recruited within each practice 
before randomisation. This process was repeated in 
waves of between ten and 15 practices, and randomisation 
was revealed at the end of each recruitment wave. Eligible 
participants were introduced to the study by local 
research nurses and gave written consent at baseline 
interview before being randomly allocated to treatment 
groups.10
Procedures
The development of the Primrose intervention and its 
content have been described previously.8,10 In summary, 
the intervention was developed from what we considered 
the best existing published evidence regarding 
cardiovascular disease risk management in severe 
mental illnesses, expert consensus (professionals and 
service users), focus groups,8 and updated systematic 
reviews. The intervention was shaped by mapping all of 
this evidence onto the Behaviour Change Wheel9 to 
identify eight key behaviour change strategies that 
health-care professionals could use to help decrease 
cardiovascular disease risk in people with severe mental 
illnesses. These included setting a behavioural goal, 
involving supportive others, creating an action plan, 
recording progress, providing positive feedback, 
reviewing progress, coping with setbacks, and forming 
habits. These strategies were incorporated into a 2-day 
training package and manual for general practice nurses.
The nurses or health-care assistants were trained on 
two occasions to use the behaviour change strategies to 
set goals that would reduce the most important risk 
factors for each participant, in a flexible collaborative 
manner. The intervention involved offering participants 
appointments on a weekly to fortnightly basis for up to 
6 months. Within the appointments, the nurse or 
health-care assistant and participant focused on agreeing 
goals to lower cardiovascular disease risk such as 
adhering to statins, improving diet or physical activity 
levels, reducing alcohol, or quitting smoking. Tools 
included health-care plans with goals and actions, 
signposting to relevant services, and initiating 
and continuing clinically indicated cardiovascular 
disease-related prescriptions including statins. 
Adherence was monitored and encouraged, and patients 
were asked if they wanted to involve supportive others 
(carers or professionals) to help improve engagement 
with goals. British Heart Foundation leaflets on keeping 
your heart healthy11 were given to intervention nurses or 
health-care assistants to distribute to participants at their 
first Primrose appointment.
Nurses or health-care assistants were each provided 
with an audio recorder and asked to record all Primrose 
intervention appointments with recruited patients. We 
used a random 20% sample of audio-taped appointments 
to determine the extent to which the intervention was 
delivered to protocol.
Nurses and health-care assistants from practices 
allocated to treatment as usual were not trained in the 
Primrose intervention. They were informed of their trial 
group allocation and received British Heart Foundation 
leaflets11 to mail out to participants. The usual clinical 
pathways for cardiovascular disease risk factors were 
continued in this group.
Outcomes
The primary outcome was difference in mean total 
cholesterol concentration for participants between 
groups at the 12-month follow-up. Secondary outcomes 
were also collected at an interim 6-month timepoint to 
monitor for high attrition at 12 months (appendix). 
Secondary outcomes at 12-month follow-up were 
cardiovascular disease risk scores, including QRISK and 
the severe mental illnesses-specific PRIMROSE 
cardiovascular disease risk score,12 blood pressure, lipid 
concentrations, HbA1c, BMI, and waist circumference. 
Behavioural measures included validated physical 
activity,13 diet14 and alcohol15 questionnaires, and questions 
on smoking status and number of cigarettes smoked. 
Other measures included quality of life,16 wellbeing,17 
medication adherence (psychiatric and cardiovascular 
disease medications including statins),18 uptake of statin 
medications, and satisfaction with services.19 Data 
regarding health-care service use and medication 
prescriptions were collected by self-report and from 
medical records for the health economic analysis 
(appendix).10
Statistical analysis
The sample size was based on a standardised mean 
difference of 0·4 for the primary outcome of total 
cholesterol concentration at 12 months, which indicated 
that 132 participants would be required per group with 
For more on QRISK see 
http://qrisk.org
See Online for appendix
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90% power and 5% level of significance. We inflated the 
sample size to account for the cluster design by assuming 
we would retain an average of four participants per 
practice and using an intraclass correlation coefficient 
(ICC) of 0·02, which has been reported as average for 
clustering in primary care trials.20 This calculation 
indicated that we required 140 participants per group in 
the analysis. Finally, we increased the target sample size 
to allow for a 20% loss to follow-up, requiring 
350 participants.
All analyses used intention-to-treat principles (ie, those 
participants with outcome data were analysed in the 
group they were randomised to). We analysed the 
primary outcome of total cholesterol concentration at 
12 months using random effects linear modelling to 
account for clustering within general practice, controlling 
for baseline total cholesterol concentration. We used 
three supportive analyses for the primary outcome. 
(1) We adjusted for large imbalances in baseline 
characteristics between randomised groups. (2) We 
adjusted for baseline predictors of missing data for 
12-month total cholesterol. We investigated these using 
random effects logistic regression; variables that were 
statistically significant (p<0·05) were included as 
predictors of missing data in the supportive analysis. 
(3) We adjusted for the number of Primrose appointments 
attended. This number was set to 0 for those participants 
in the treatment-as-usual group. All supportive analyses 
also controlled for baseline total cholesterol.
We analysed continuous secondary outcomes using 
random effects linear modelling and smoking status 
(current vs non-current) using random effects logistic 
regression. We adjusted all analyses for baseline values 
of the outcome. We did all analyses using Stata version 14. 
The primary economic analysis was from the 
health-care cost perspective over the duration of the trial 
(12 months). We calculated the incremental cost per 
quality-adjusted life-year (QALY) gained and the 
probability of cost-effectiveness for a range of values of 
willingness to pay for a QALY gained (appendix).
We designed and applied fidelity checklists to 
appointment transcripts to assess fidelity to the 
intervention. We generated a percentage score for each 
appointment by dividing the total number of intervention 
components delivered by the maximum number of 
intervention components that should have been delivered.
We had an external Trial Steering Group, as agreed by 
the funding body. The trial is registered with Current 
Controlled Trials, number ISRCTN13762819.
Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. The corresponding author had full access to 
all the data in the study and had final responsibility for 
the decision to submit for publication. 
Results
We recruited general practices from Dec 10, 2013, to 
Sept 30, 2015; participant recruitment occurred between 
133 general practices invited to take part 44 excluded
 24 not interested
 10 unable to support the study
 10 not enough patients to approach
38 general practices with 155 patients assigned to 
 intervention plus treatment as usual
 123 received intervention
 32 did not receive intervention
 1 died
 18 not contactable
 3 unwell
 1 full-time employment 
 6 not contacted
 3 moved practice 
18 patients lost to 12-month follow-up
 1 died
 10 withdrew
 5 not contactable
 1 too unwell
 1 blood samples missing
38 general practices with 137 patients included in 
 the intention-to-treat analysis
38 general practices with 172 patients assigned 
 to treatment as usual
19 patients lost to 12-month follow-up
 3 died
 5 withdrew
 4 not contactable
 3 admitted to hospital
 3 blood samples missing
 1 moved out of the area
38 general practices with 152 patients included in  
 the intention-to-treat analysis
1 patient not eligible for study and excluded
   from  analysis
76 general practices randomised with 327 patients
 randomly allocated
891 patients screened
564 excluded
 363 did not meet inclusion criteria
 196 declined
 5 other reasons
 1 unwell
 2 moved out of the area
 2 not contactable
3982 patients invited to take part from 76 general practices
3091 excluded
 2271 not contactable
 792 declined
 28 other reasons
 9 unwell
 1 declined blood test
 4 moved practice
 1 out of the country 
 1 too busy
 1 unable to speak English
 11 general practice excluded
  89 general practices recruited 13 excluded
 1 no longer interested
 2 lost resources to support the study
 1 not enough patients to approach
 9 unable to recruit
Figure: Trial profile
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May 9, 2014, and Feb 10, 2016, with 12 months’ follow-up 
between May 6, 2015, and Feb 17, 2017. We randomly 
assigned 76 general practices from diverse regions across 
England to the Primrose intervention group (n=38 with 
155 patients) or to the treatment-as-usual group (n=38 
with 172 patients; figure). 41 professionals (22 health-care 
assistants, 18 nurses, and one general practitioner) were 
trained to deliver the Primrose intervention. In three of 
the 38 general practices, two members of staff were 
trained because the original staff member left the practice 
part way through the study.
Most baseline characteristics of participants were 
similar between the two groups (table 1). About half the 
participants had a record of bipolar disorder, roughly a 
third had a record of schizophrenia or schizoaffective 
disorder, and almost a fifth had other psychoses (table 1). 
About half the participants were current smokers and 
total cholesterol concentrations were raised (table 1). 
Mean BMI was above the threshold for obesity with high 
mean waist circumferences (table 1). Baseline 
characteristics of participants that appeared unbalanced 
between the two groups and were likely to be associated 
with the outcomes included having a mental health key 
worker, sex, living independently, being prescribed a 
statin or second-generation antipsychotic, and having a 
record of diabetes (table 1).
At the 12-month follow-up, all 76 general practices 
remained in the study and we analysed 137 (88%) of 
155 patients in the Primrose intervention group and 
152 (88%) of 172 patients in the treatment-as-usual group 
for the primary outcome (figure). The number of 
participants with 12-month follow-up data exceeded the 
requirements of the original sample size calculation. 
The primary outcome measure of total cholesterol in the 
two groups at 12 months did not differ at the 5% level 
(5·4 mmol/L [SD 1·1] in the Primrose intervention 
group vs 5·5 mmol/L [1·1] in the treatment-as-usual 
group; mean difference estimate 0·03, 95% CI 
–0·22 to 0·29; p=0·788; table 2). The mean total 
cholesterol decreased in both groups over the 12-month 
follow-up period by 0·22 mmol/L (SD 1·1) in the 
Primrose intervention group and by 0·36 mmol/L (1·1) 
in the treatment-as-usual group. The adjusted (for 
baseline total cholesterol and randomised group) ICC 
for the primary outcome at 12 months was 0·07 (95% CI 
0·02–0·29).
The results from the supportive analyses were 
consistent with what was observed for the primary 
analysis when adjusting for the baseline differences in 
participants (mean difference estimate 0·09, 95% CI 
–0·16 to 0·34; p=0·47) or when adjusting for variables 
that predicted missing data on the primary outcome 
(0·06, –0·19 to 0·30; p=0·65) and adjusting for number 
of Primrose intervention appointments attended (0·02, 
–0·31 to 0·36; p=0·89). These predictors were being in 
full-time employment, having a mental health key 
worker, or being treated for hypertension.
Secondary clinical outcomes did not differ between the 
groups at 12 months (table 2). Coefficients were close to 
zero effect with 95% CIs spanning unity and zero (table 2). 
This outcome held true for the cardiovascular risk factors, 
including BMI, waist circumference, HDL cholesterol, 
total:HDL cholesterol, blood pressure, smoking, physical 
activity, and fibre-related or fat-related diet. Satisfaction 
Primrose intervention 
group (n=155)
Treatment-as-usual 
group (n=172)
Sex
Male 67/155 (43%) 87/171 (51%)
Female 88/155 (57%) 84/171 (49%)
Age (years) 51 (10) 51 (10)
Ethnicity
White 134/154 (87%) 155/171 (91%)
Black 11/154 (7%) 5/171 (3%)
Asian 5/154 (3%) 5/171 (3%)
Other 4/154 (3%) 6/171 (4%)
Townsend quintile
1 (least deprived) 22/136 (16%) 17/119 (14%)
2 7/136 (5%) 11/119 (9%)
3 17/136 (13%) 11/119 (9%)
4 30/136 (22%) 28/119 (24%)
5 (most deprived) 60/136 (44%) 52/119 (44%)
Marital status
Single 66/154 (43%) 68/170 (40%)
Married or cohabiting 59/154 (38%) 64/170 (38%)
Separated or divorced 25/154 (16%) 34/170 (20%)
Widowed 4/154 (3%) 5/170 (3%)
Lives independently 115/155 (74%) 109/170 (64%)
Employment
Unemployed 71/155 (46%) 76/171 (44%)
Part-time paid employment 18/155 (12%) 26/171 (15%)
Full-time paid employment 13/155 (8%) 22/171 (13%)
Paid employment with paid support or employment 
training
1/155 (1%) 1/171 (1%)
Employed (paid to limit without affecting benefits) 4/155 (3%) 1/171 (1%)
Voluntary work 19/155 (12%) 22/171 (13%)
In education 8/155 (5%) 7/171 (4%)
Looking after home and family 13/155 (8%) 31/171 (18%)
Retired from paid work 27/155 (17%) 27/171 (16%)
Primary diagnosis
Schizophrenia or schizoaffective disorder 54/155 (35%) 51/171 (30%)
Bipolar affective disorder 71/155 (46%) 88/171 (51%)
Other psychoses 30/155 (19%) 32/171 (19%)
Has mental health key worker 68/155 (44%) 53/171 (31%)
Has support worker 27/155 (17%) 25/171 (15%)
On Care Programme Approach 103/149 (69%) 101/154 (66%)
Cholesterol (mmol/L)
Total cholesterol 5·7 (0·9) 5·9 (1·0)
HDL 1·3 (0·4) 1·3 (0·5)
LDL 3·5 (0·8) 3·5 (0·8)
Total:HDL 4·8 (1·4) 4·9 (2·1)
(Table 1 continues on next page)
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with primary care services on the client satisfaction scale 
was high in both groups, with no differences between the 
groups in terms of wellbeing on the Warwick–Edinburgh 
Mental Well-being Scale at 12 months (table 2). Adherence 
to medications for physical and psychiatric conditions, as 
recorded on the Morisky scales, was also similar in both 
groups (table 2). Among the 155 participants in the 
Primrose intervention group, attendance at appointments 
was fair with 72 (46%) attending six or more appoint-
ments, 36 (23%) attending two to five appointments, 
15 (10%) attending one appointment, and 32 (21%) people 
attending no appointments.
Most research nurses who collected data correctly 
guessed the treatment allocation despite being masked—
of those participants who responded, the nurses correctly 
guessed the allocation of 108 (75%) of 144 in the Primrose 
group compared with 133 (82%) of 163 in the 
treatment-as-usual group.
30 serious adverse events were reported for 25 people 
(seven events for seven participants in the intervention 
group and 23 events for 18 participants in the control 
group). One death, three psychiatric hospital admissions, 
and three general hospital admissions were reported in 
the intervention group and three deaths, 11 psychiatric 
hospital admissions for nine people, seven general 
hospital admissions for six people, one admission to a 
crisis house, and one diagnosis of cancer were reported 
in the control group.
Total health-care costs were lower in the Primrose 
intervention group than the treatment-as-usual group 
(adjusted mean £1286 [SE 178] vs £2182 [328]; mean 
difference –£895, 95% CI –1631 to –160; p=0·012), and 
there was a significant reduction in the number and cost 
of mental health inpatient stays in the intervention group 
compared with the control at 12 months (£157 [135] vs 
£956 [313]; –£799, –1480 to –117; p=0·018; appendix). In 
the Primrose group, more eligible people with severe 
mental illnesses were accessing services for smoking, 
weight reduction, and diabetes at months 6 and 12 than 
in the treatment-as-usual group, but relevant health-care 
promotion activities occurred in both groups (appendix).
Adjusting for baseline differences, the intervention 
group had a mean of 0·769 QALYs (95% CI 0·751 to 0·787) 
compared with a mean of 0·780 for treatment as usual 
(0·764 to 0·796), with a difference in QALYs of 
–0·011 (–0·034 to 0·011; p=0·41; appendix). The mean 
12-month health-care cost per patient for the Primrose 
intervention (including intervention costs but excluding 
those participants who did not attend and training) was 
£2580 (SE 249; 95% CI 1899 to 3261) with a total mean 
cost of £3404 (401; 2467 to 4340) for treatment as usual, 
with a cost difference of –£824 (95% CI –568 to 1079; 
p=0·11) in favour of the Primrose group. Because the 
intervention had a lower mean cost per patient, but 
slightly fewer QALYs, there is a greater probability that 
the intervention is cost-effective at lower values of 
willingness to pay for a QALY gain, with an 
Primrose intervention 
group (n=155)
Treatment-as-usual 
group (n=172)
(Continued from previous page)
Triglycerides (mmol/L) 2·3 (1·7) 2·3 (1·3)
HbA1c (mmol/mol) 41 (11) 39 (8)
Glucose (mmol/L)
Fasting 5·5 (1·4) 5·5 (0·8)
Non-fasting 6·1 (1·3) 5·4 (0·9)
Blood pressure (mm Hg)
Systolic 127 (17) 129 (19)
Diastolic 82 (11) 82 (11)
BMI (kg/m²) 32 (6) 32 (6)
Waist circumference (cm) 107 (16) 108 (15)
AUDIT score 2 (0–7) 3 (0–7)
History of heavy drinking 35/155 (23%) 38/171 (22%)
Smoking status
Non-smoker 40/155 (26%) 47/171 (27%)
Ex-smoker 35/155 (23%) 44/171 (26%)
Current smoker 80/155 (52%) 80/171 (47%)
Cigarettes smoked per day for current smokers 20 (10–20) 15 (10–20)
QRISK2-2016 7·0 (3·8–14·9) 8·1 (3·5–14·2)
Framingham
Lipid 10·7 (6·4–17·3) 10·5 (6·0–18·9)
BMI 11·9 (6·9–20·6) 12·2 (6·2–21·2)
Primrose score
Lipid 3·7 (2·4–7·0) 3·7 (2·1–6·9)
BMI 4·7 (2·8–8·0) 4·8 (2·5–7·5)
DINE score
Fibre 29 (20–38) 32 (23–41)
Fat 29 (22–37) 31 (22–40)
Unsaturated fat 9 (8–10) 9 (9–11)
IPAQ activity total MET (min) 1386 (304–3564) 1200 (396–3111)
Type 1 diabetes 0 1/171 (1%)
Type 2 diabetes 22/155 (14%) 12/171 (7%)
Diagnosis of diabetes in past 5 years 19/155 (12%) 13/171 (8%)
Prescription
Antihypertensive drug 45/155 (29%) 48/171 (28%)
Statin 36/155 (23%) 27/171 (16%)
Diabetes drug 20/155 (13%) 13/171 (8%)
Antidepressant 90/155 (58%) 92/171 (54%)
First-generation antipsychotic drug 21/155 (14%) 22/171 (13%)
Second-generation antipsychotic drug 83/155 (54%) 109/171 (64%)
QALYs (area under curve)
EQ-5D-5L 0·734 (0·249) 0·775 (0·209)
WEMWBS score 42 (12) 43 (10)
MMS
Psychiatric medication 6 (5–8) 7 (5–7)
Cardiovascular disease prevention medication 7 (6–8) 7 (6–8)
Data are n/N (%), mean (SD), or median (IQR). HbA1c=glycated haemoglobin. BMI=body-mass index. AUDIT=Alcohol 
Use Disorders Identification Test. DINE=Dietary Instrument for Nutrition Education. IPAQ=International Physical 
Activity Questionnaire. MET=metabolic equivalent of task. QALY=quality-adjusted life-year. EQ-5D-5L=five-level 
EuroQol five-dimensional. WEMWBS=Warwick–Edinburgh Mental Well-being Scale. MMS=Morisky Scale of Adherence.
Table 1: Participant characteristics at baseline
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89% probability it is cost-effective at a £20 000 willingness 
to pay for a QALY gained and 98% at a £0 willingness to 
pay for a QALY gained (appendix).
A moderate level of adherence to the intervention 
manual (including use of behaviour change techniques) 
was achieved with 67·7% of all intervention components 
delivered to protocol. The mean percentage score for 
nurses (79·5% [SD 15·2]) was significantly higher than 
the mean percentage score for health-care assistants 
(64·3% [16·5]; t=2·23; p=0·037). Regarding statin 
prescriptions, few statins appeared to be initiated in 
either group by 12 months (table 2).
Discussion
In this cluster randomised trial of the practitioner-led 
Primrose intervention, the primary outcome of total 
cholesterol concentration at 12 months did not differ 
between intervention and control groups in general 
practices in England. The manualised Primrose 
intervention was developed from the best published 
evidence, with a wide range in expert input, including 
service users with severe mental illnesses and health-care 
professionals. It incorporated behavioural scientific 
theory, and fidelity to the intervention manual was 
acceptable. However, evidence that statin initiation or 
adherence was addressed in either group was scarce.
The intervention was associated with fewer admissions 
for mental health in terms of adverse events, and this 
result was substantiated by the cost-effectiveness analysis, 
which revealed significantly lower costs for admissions for 
mental health and between an 89% and 98% probability 
that the Primrose intervention is cost-effective. A strength 
of this analysis is that the outcomes were collected from 
medical records with rare missing data. The probability 
that the Primrose intervention is cost-effective at 
12 months was heavily dependent on the willingness to 
pay for a QALY gain, with low values of willingness to pay 
for a QALY gained having a higher probability of being 
cost-effective. Thus, the intervention is cost saving, but for 
fewer QALYs. Most of the cost savings were a result of a 
reduction in the cost of inpatient mental health care in the 
Primrose group. Whether the EuroQol five-dimensional 
questionnaire and QALYs are the correct denominator for 
a health prevention intervention can be questioned, 
particularly given that most interventions were designed 
to have an impact on cardiovascular health outcomes in 
the distant future.
For this pragmatic trial, we designed an intervention 
that aimed to reflect real-life clinical settings in which 
participants with severe mental illnesses present with 
multiple cardiovascular risk factors which require 
modification simultaneously, and in a collaborative 
manner between health-care professionals and patients. 
Choosing a single outcome measure in such 
circumstances is difficult, but because all our participants 
had raised total cholesterol concentrations, we chose 
difference in total cholesterol as the main outcome 
measure. This outcome measure would not capture 
changes in smoking or blood pressure, but it might be 
affected by changes in diet, exercise, or weight, which 
were all goals in the intervention. However, no differences 
in cholesterol concentrations were seen between groups. 
Although we considered choosing a cardiovascular 
disease risk score as the main outcome (involving more 
component modifiable cardiovascular disease risk 
factors), these risk scores are not sensitive to change 
because they are affected so heavily by an individual’s age 
and sex. There is no evidence that any other cardiovascular 
disease risk factors among our secondary outcomes 
differed between groups, so our choice of cholesterol as 
the primary outcome is unlikely to explain the absence of 
main effects in the Primrose intervention group.
Other limitations include the fact that only a few people 
with severe mental illnesses per practice participated, 
which could in part have been due to being invited to 
participate in a randomised controlled trial that involved 
having several blood tests, therefore uptake might be 
higher in clinical settings. The small number per practice 
Primrose 
intervention 
group (n=155)
Treatment-as-
usual group 
(n=172)
Mean difference 
estimate (95% CI)*
p value
Cholesterol (mmol/L)
Total 5·4 (1·1) 5·5 (1·1) 0·03 (–0·22 to 0·29) 0·788
HDL 1·3 (0·5) 1·3 (0·4) –0·01 (–0·07 to 0·05) 0·64
LDL† 3·3 (1·0) 3·3 (0·9) ·· ··
Total:HDL 4·5 (1·4) 4·4 (1·3) 0·13 (–0·16 to 0·42) 0·36
HbA1c (mmol/mol) 41 (11) 40 (9) 0·14 (–1·36 to 1·65) 0·85
Blood pressure (mm Hg)
Systolic 125 (16) 126 (17) –0·97 (–4·34 to 2·40) 0·57
Diastolic 80 (10) 80 (10) 0·56 (–1·69 to 2·81) 0·63
BMI (kg/m²) 32 (7) 32 (7) –0·44 (–1·18 to 0·30) 0·24
Waist circumference (cm) 106 (16) 107 (15) –0·55 (–2·33 to 1·23) 0·55
AUDIT score 2 (0–5) 3 (0–7) –0·51 (–1·45 to 0·42) 0·28
Smoking
Current smoker 62/134 (46%) 68/155 (44%) 0·79 (0·36 to 1·70)* 0·54
QRISK2-2016 7·6 (3·7–14·5) 8·5 (3·6–12·9) 0·46 (–0·49 to 1·41) 0·35
Framingham
Lipid 9·4 (5·9–16·8) 9·9 (5·4–16·7) 0·40 (–0·98 to 1·77) 0·57
BMI 9·9 (6·8–19·3) 12·5 (6·8–20·0) –0·39 (–2·03 to 1·26) 0·65
Primrose score
Lipid 3·5 (2·3–6·9) 3·8 (1·9–6·9) –0·42 (–1·35 to 0·51) 0·38
BMI 4·3 (2·7–7·6) 4·5 (2·7–8·4) –0·80 (–2·06 to 0·46) 0·21
DINE score
Fibre 30 (22–37) 31 (23–40) –0·32 (–2·79 to 2·14) 0·80
Fat 30 (23–35) 29 (22–37) 0·04 (–1·95 to 2·02) 0·97
Unsaturated fat 9 (8–11) 9 (8–11) 0·06 (–0·32 to 0·44) 0·75
IPAQ activity total MET (min) 1386 
(462–4239)
1371 
(438–4158)
–139·6 
(–1323·9 to 1044·7)
0·82
Type 1 diabetes‡ 0 1/163 (1%) ·· ··
Type 2 diabetes‡ 24/144 (17%) 14/163 (9%) ·· ··
(Table 2 continues on next page)
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could have implications for scalability; however, as the 
number was smaller, it was feasible for practice nurses or 
health-care assistants to integrate into their normal 
clinical workload, and arguably a higher number of 
patients might have made the delivery of the intervention 
less feasible. If the number of patients with severe mental 
illnesses within a practice were small, a service could be 
offered by a single nurse to a cluster of practices, making 
the delivery of training and case-load more cost-effective.
Another limitation was that the intervention did not 
target psychotropic medication management, which can 
have an effect on obesity and metabolic parameters for 
people with severe mental illnesses. The ICC for the 
primary outcome was high between practices, indicating 
that effects differed more than we expected between 
individual general practices (the clusters). This large 
practice effect might indicate that the intervention was 
delivered variably by different professionals in different 
settings, which is supported by the differences we 
observed in fidelity scores between nurses and health-care 
assistants.
The economic findings were particularly caused by a 
reduction in admissions for mental health at 12 months 
in the Primrose group. We cannot rule out the possibility 
that this reduction occurred by chance.
The participants and practices that agreed to take part in 
the Primrose trial might not be representative of the wider 
populations with severe mental illnesses and raised 
cardiovascular disease risk factors because they could have 
been more motivated to address their physical health. We 
compared our trial participants to a sample of 
38 824 patients with severe mental illnesses from 
430 general practices in England used in our previous 
work.12 The characteristics were similar in terms of age 
(51 years in this trial vs 49·5 years in our previous study) 
and sex (male participants accounted for 47% in both 
samples), with a slightly higher mean BMI (32 kg/m² vs 
28 kg/m²) and total cholesterol (5·8 mmol/L vs 
5·5 mmol/L) in this trial. This outcome is probably due to 
our trial inclusion criteria targeting participants with 
raised cardiovascular disease risk factors. Both studies had 
the same HDL cholesterol concentration (1·3 mmol/L) 
and number of current smokers (49%). Our trial sample 
also had higher deprivation (participants living in the most 
deprived areas was 44% vs 23%), which could have been 
due to us targeting general practices with larger severe 
mental illnesses lists in urban areas. However, a strength 
of our study was the geographical spread of recruited 
general practices that included both rural and urban 
practices across the north and south of England.
Our inclusion criteria for people with severe mental 
illnesses included those individuals with schizophrenia, 
bipolar, and other psychoses; however, we did not include 
broader definitions of severe mental illnesses—eg, 
personality disorder.21 Therefore, the findings of our 
study might not apply to people outside our definition of 
severe mental illnesses.
The practices randomised to the treatment-as-usual 
group could have provided much better health care to 
their severe mental illnesses participants than would 
have been observed in routine practices outside a trial 
environment, partly because they were practices with an 
interest in research and an interest in severe mental 
illnesses and cardiovascular disease, but also because 
they were aware that their patients with raised 
cardiovascular disease risk factors would not receive the 
Primrose intervention when they were allocated to 
treatment as usual. The economic analysis confirmed 
that relevant cardiovascular disease health promotion 
activities were accessed in both groups during the 
duration of the trial. The high levels of satisfaction in 
both groups (27/32 on the Client Satisfaction 
Questionnaire-8 items) might also reflect good health 
care being provided in both groups. The mean total 
cholesterol concentrations did decrease in both groups of 
the trial over the 12 months of follow-up.
Although the Primrose intervention seemed acceptable 
to participants and to general practices, we cannot 
recommend it over treatment as usual in England in 
terms of improving medical outcomes. However, it did 
result in cost savings and reduced admissions, a finding 
worthy of further exploration.
Primrose 
intervention 
group (n=155)
Treatment-as-
usual group 
(n=172)
Mean difference 
estimate (95% CI)*
p value
(Continued from previous page)
Prescription
Antihypertensive drug‡ 41/144 (28%) 44/163 (27%) ·· ··
Statin 38/144 (26%) 31/163 (19%) 1·11 (0·50 to 2·49)* 0·80
Newly prescribed statin at 
12 months
9/144 (6%) 10/163 (6%) 1·01 (0·38 to 2·71)* 0·99
Diabetes drug‡ 22/144 (15%) 15/163 (9%) ·· ··
Antidepressant‡ 85/144 (59%) 83/163 (51%) ·· ··
First-generation 
antipsychotic drug‡
29/144 (20%) 21/163 (13%) ·· ··
Second-generation 
antipsychotic drug‡
77/144 (53%) 96/163 (59%) ·· ··
QALYs (area under curve)
EQ-5D-5L 0·775 (0·232) 0·782 (0·227) –0·011 
(–0·034 to 0·011)
0·41
WEMWBS score 43 (12) 45 (10) –1·53 (–3·52 to 0·45) 0·13
MMS
Psychiatric medication 7 (5–8) 7 (5–8) 0·14 (–0·23 to 0·52) 0·46
Cardiovascular disease 
medication
7 (5–8) 7 (6–8) 0·25 (–0·33 to 0·83) 0·40
CSQ-8 27 (24–31) 27 (24–31) 0·31 (–0·83 to 1·45) 0·59
Data are mean (SD), n/N (%), or median (IQR). All results were adjusted for baseline values apart from CSQ-8, which 
was only collected at the 12-month follow up. HbA1c=glycated haemoglobin. BMI=body-mass index. AUDIT=Alcohol 
Use Disorders Identification Test. DINE=Dietary Instrument for Nutrition Education. IPAQ=International Physical 
Activity Questionnaire. MET=metabolic equivalent of task. QALY=quality-adjusted life-year. EQ-5D-5L=five-level 
EuroQol five-dimensional. WEMWBS=Warwick–Edinburgh Mental Well-being Scale. MMS=Morisky Scale of Adherence. 
CSQ-8=Client Satisfaction Questionnaire-8 items. *Odds ratio as indicated. †Analysis not done because of large 
amount of missing data (data available for 153 [47%] of 326 participants). ‡For descriptive analysis.
Table 2: Outcomes at 12 months’ follow-up
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The mortality gap between people with and without 
severe mental illnesses continues to widen in UK general 
practices,2 so it is essential that treatment as usual 
continues to incorporate all of the evidence-based 
interventions for cardiovascular disease prevention in an 
integrated way, which has the best chance of reducing 
the main excessive risk factors in people with severe 
mental illnesses. These risks include high rates of 
smoking, which can be amenable to targeted cessation 
support,22 obesity, which can be managed with 
pharmacological and behavioural techniques,23 and 
prescribing statins, which we have previously shown to 
reduce cholesterol concentrations in people with severe 
mental illnesses with effects comparable to the general 
population.6
All participants in both groups of the Primrose trial 
received screening for cardiovascular disease risk factors 
and feedback before being randomly assigned, which is 
not observed for everyone in routine general practice 
care.24 It is important that cardiovascular disease 
screening is maintained as policy in routine primary care 
for people with severe mental illnesses, since the 
application of risk scores and then prescribing statins 
could well be cost-effective in the short term and 
long term in severe mental illnesses.7 The findings from 
the Primrose trial mirror findings from an individualised 
randomised controlled trial25 in the USA of tailored 
cardiovascular disease care delivered in a behavioural 
health home in an urban psychiatric centre, which 
compared 447 outpatients with severe mental illnesses 
and cardiovascular disease risk factors. Although 
health-care quality improved in the integrated 
behavioural health home, the results did not translate 
into improved medical outcomes for the people with 
severe mental illnesses, over and above usual care. An 
accompanying editorial26 argued that these integrated 
care models contain crucial elements of physical health 
care, but that they might struggle to show benefits in trial 
settings for medical outcomes, given the heterogeneous 
nature of the target population, as well as their varied 
risk factor profiles. Additionally, the study authors note 
that, as in our trial, screening and feedback in their 
treatment-as-usual group could have been enough to 
improve outcomes in the usual care group. Large-scale 
observational studies, with routine data from both 
primary and secondary care settings, might be better 
suited than trials to evaluate whether evidence-based 
screening and interventions are being delivered to people 
with severe mental illnesses, and ultimately whether 
these interventions are decreasing the cardiovascular 
disease mortality gap in this group of people.
In summary, the more intense behavioural intervention 
of Primrose was not more effective than treatment as 
usual in primary care, in which treatment as usual 
involved active screening and feedback to people with 
raised cardiovascular risk factors. The intervention was 
well attended and costs seemed to be reduced and 
psychiatric hospital admissions were reduced in the 
Primrose group. The absence of effectiveness in our 
primary outcome might be explained by the infrequent 
prioritisation of statins in both trial groups.
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